Table 1:
Baseline characteristics
| Diflunisal (n=35) | Control (n=69) | p value | |
|---|---|---|---|
| Age, years | 73.8 ± 7.0 | 76.8 ± 6.5 | 0.03 |
| Male | 34 (97.1%) | 67 (97.1%) | 0.99 |
| Race: white | 31 (91.2%) | 53 (76.8%) | 0.20 |
| Time from diagnosis, years | 0.41 ± 0.50 | 0.47 ± 0.9 | 0.72 |
| Hypertension | 13 (37%) | 12 (17%) | 0.02 |
| Diabetes | 5 (14%) | 10 (14%) | 1.00 |
| Coronary Artery Disease | 8 (23%) | 21 (30%) | 0.45 |
| Atrial fibrillation | 21 (60%) | 47 (68%) | 0.42 |
| Creatinine, mg/dL | 1.14 ± 0.33 | 1.41 ± 0.43 | < 0.01 |
| eGFR mL/min/1.73m2 | 67.3 ± 17.4 | 53.2 ± 17.6 | < 0.001 |
| BNP, pg/mL | 335.0 ± 365.6 | 5 ± 296.1 | < 0.01 |
| logBNP | 5.48 ± 0.8 | 6.07 ± 0.7 | < 0.001 |
| Troponin I, ng/ | 0.1 ± 0.1 | 0.2 ± 0.34 | 0.09 |
| NYHA class | |||
| I | 13 (37.1%) | 17 (24.6%) | |
| II | 16 (45.7%) | 23 (33.3%) | |
| III | 5 (14.3%) | 26 (37.7%) | |
| Diuretic use | 24 (68.6%) | 63 (91.3%) | < 0.01 |
| Beta blocker use | 18 (51.4%) | 46 (66.7%) | 0.13 |
| ACEi or ARB use | 10 (28.6%) | 33 (47.8%) | 0.06 |
| Left ventricular ejection fraction, % | 53.1 ± 12.0 | 45.0 ± 11.5 | < 0.01 |
| Interventricular septal thickness, mm | 16.6 ± 2.7 | 15.8 ± 2.3 | 0.11 |
| Posterior wall thickness, mm | 16.5 ± 2.2 | 15.8 ± 2.4 | 0.01 |
Continuous variables expressed as mean +/− standard deviation, and categorical variables as number (%). eGFR was calculated using the CKD-Epi equation.